MedTrace Logo

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

NCT00448786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2011-01-21

No results posted yet for this study

Summary

The study involves the use of three different dosing regimens of AMG 706 in patients with advanced solid tumors to see how the drug affects the gallbladder size and function. The study will be conducted in 11 sites in the US and Australia. A total of 48 patients will be enrolled in the study with the possibility of enrolling 8 more in each treatment arm.

Conditions

Interventions

DRUG

AMG 706

Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off

DRUG

AMG 706

Arm C - 75 mg BID 5-days on, 2-days off

DRUG

AMG 706

AMG 706 125 mg daily continuously (Arm A)

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-12-31
Completion
2009-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448786 on ClinicalTrials.gov